The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
|Articles|November 3, 2016
EUPATI Prepares to Celebrate 5th Anniversary in Brussels
Author(s)Philip Ward
EUPATI celebrates its 5th Anniversary in Brussels by staging a free workshop.
Advertisement
As the fifth anniversary of the European Patients’ Academy (EUPATI) approaches, the organization is getting to stage a free workshop, “All Aboard to a Better Health Future”, to be held in Brussels on December 14th.
According to a statement from EUPATI, “Patient involvement in medicines research and development is a major driving force for transformational change in healthcare and the development of innovative medicines. This is why the EUPATI Project is such an exciting and unique opportunity – offering patients and patient advocates education and information on how new therapies are being developed and regulated.”
EUPATI works at the national level, implementing initiatives in 18 countries. The national teams offer workshops and tutorials for patient groups, interacting with professionals from clinical research, ethics committees, regulators, and the pharmaceutical industry.
“The challenge now is to bring all these initiatives and experiences together to create value for everyone. For the patient this means better understanding of research and innovation, leading to better therapies and eventually to improved health and well being,” EUPATI noted.
EUPATI is a pan-European Innovative Medicines Initiative (
Advertisement
Related to this article
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
3
Where AI Governance in Clinical Development Falls Short
4
Syneos Health, Optum Partner on Adaptive Clinical Development Model
5